During the last session, Tarsus Pharmaceuticals Inc (NASDAQ:TARS)’s traded shares were 0.37 million, with the beta value of the company hitting 1.10. At the end of the trading day, the stock’s price was $32.04, reflecting an intraday loss of -0.53% or -$0.17. The 52-week high for the TARS share is $40.40, that puts it down -26.09 from that peak though still a striking 60.77% gain since the share price plummeted to a 52-week low of $12.57. The company’s market capitalization is $1.20B, and the average trade volume was 726.90K shares over the past three months.
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) trade information
Tarsus Pharmaceuticals Inc (TARS) registered a -0.53% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.53% in intraday trading to $32.04, hitting a weekly high. The stock’s 5-day price performance is -1.23%, and it has moved by -7.32% in 30 days. Based on these gigs, the overall price performance for the year is 121.88%.
Tarsus Pharmaceuticals Inc (TARS) estimates and forecasts
Statistics show that Tarsus Pharmaceuticals Inc has underperformed its competitors in share price, compared to the industry in which it operates. Tarsus Pharmaceuticals Inc (TARS) shares have gone up 141.99% during the last six months, with a year-to-date growth rate less than the industry average at 8.01% against 12.90. In the rating firms’ projections, revenue will increase 471.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 17.83M as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 23.59M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -132.82%. While earnings are projected to return 11.75% in 2024.
TARS Dividends
Tarsus Pharmaceuticals Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
